Ibandronate Use in Osteoporotic Vertebral Fractures: A Retrospective Clinical Study Integrated with Exploratory Network Pharmacology and Cross-Cohort Transcriptomic Analysis
Yazarlar (4)
Doç. Dr. Mehmet Albayrak İstanbul Rumeli Üniversitesi, Türkiye
Ersin Guner
Ankara Numune Education And Research Hospital, Türkiye
Ankara Numune Education And Research Hospital, Türkiye
Doç. Dr. Fatih UĞUR Kastamonu Üniversitesi, Türkiye
Dr. Öğr. Üyesi İbrahim Yılmaz Dr. Ismail Fehmi Cumalioglu City Hospital, Türkiye
| Makale Türü |
Özgün Makale
(SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
|
||
| Dergi Adı | Biomedicines (Q1) | ||
| Dergi ISSN | 2227-9059 Dergi Bilgileri (2026) | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | Türkçe | Basım Tarihi | 06-2026 |
| Kabul Tarihi | – | Yayınlanma Tarihi | 10-06-2026 |
| Cilt / Sayı / Sayfa | 14 / 6 / – | DOI | 10.3390/biomedicines14061315 |
| Makale Linki | https://doi.org/10.3390/biomedicines14061315 | ||
| UAK Araştırma Alanları |
Ortopedi ve Travmatoloji
|
||
| Özet |
| Background Ibandronate is a nitrogen-containing bisphosphonate used in osteoporosis; however, its relationship with vertebral-fracture-related outcomes, pain trajectories, and broader inflammatory–skeletal signaling remains incompletely characterized. Methods This retrospective observational study included patients with osteoporosis categorized according to ibandronate exposure. The primary outcome was new vertebral fracture occurrence, and the secondary outcome was change in pain severity assessed using the Visual Analog Scale (VAS). Multivariable regression, sensitivity analyses, and exploratory network-pharmacology, transcriptomic, and molecular docking analyses were performed. Results Forty patients (20 ibandronate, 20 control) were included. Ibandronate use was associated with numerically lower vertebral fracture occurrence, although this did not reach statistical significance in crude or adjusted analyses. Greater pain reduction was observed in unadjusted analyses but was attenuated after multivariable adjustment, and baseline heterogeneity should be considered when interpreting between-group differences. Radiological outcomes did not differ significantly between groups. Exploratory systems-level analyses identified enrichment patterns involving inflammatory signaling, osteoclast differentiation, cytokine-associated pathways, and skeletal regulatory processes; however, these findings should be interpreted as hypothesis-generating and not as evidence of causal biological mechanisms. Conclusions In this exploratory, hypothesis-generating study, ibandronate use was associated with trends toward lower vertebral … |
| Anahtar Kelimeler |
| ibandronate | network pharmacology | osteoporosis | pain | transcriptomics | vertebral fracture |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Google Scholar | 1 |